[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340864-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340864-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-targeting-of-the-human-epidermal-growth-factor-receptor-2-her2-genes-across-various-cancers","Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers","","Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family of transmembrane glycoproteins with tyrosine kinase activity that regulates signaling for normal growth and differentiation. When signaling is disrupted, uncontrolled cellular growth can result. HER2 is implicated in at least eight malignancies and is associated with aggressive disease behavior, poor prognosis, and higher progression and mortality. The review synthesizes up-to-date knowledge on receptor biology, diagnostic testing, and the evolving role of anti-HER2 targeted therapies across cancer types.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-targeting-of-the-human-epidermal-growth-factor-receptor-2-her2-genes-across-various-cancers/340864/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-targeting-of-the-human-epidermal-growth-factor-receptor-2-her2-genes-across-various-cancers/340864.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological role does HER2 play in cells?","Question",{"text":63,"@type":64},"HER2 is a tyrosine kinase receptor involved in transmitting cellular signals that control normal cell growth and differentiation. If signaling goes awry, it can drive dysregulated cellular growth.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is HER2 considered clinically important in cancer?",{"text":68,"@type":64},"HER2 positivity is linked to aggressiveness and poor prognosis, with higher rates of progression and mortality. It is implicated in multiple malignancies with varying prevalence.",{"name":70,"@type":61,"acceptedAnswer":71},"How has anti-HER2 targeted therapy evolved across cancer types?",{"text":72,"@type":64},"Anti-HER2 therapy was first developed and studied in breast cancer, where major therapeutic advances have occurred. The review highlights growing incorporation of anti-HER2 strategies into other cancer types and discusses future therapies under development.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340864,1790167655,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Review  \nMolecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers  \nElizabeth Rubin *, Khine S. Shan , Shivani Dalal, Dieu Uyen Dao Vu, Adriana M. Milillo-Naraine, Delia Guaqueta and Alejandra Ergle  \nCitation: Rubin, E.; Shan, K.S.; Dalal, S.; Vu, D.U.D.; Milillo-Naraine, A.M.; Guaqueta, D.; Ergle, A. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. Int. J. Mol. Sci. 2024, 25, 1064. [https://](https://)[ ](https://)[doi.org/10.3390/ijms25021064](doi.org/10.3390/ijms25021064)  \nAcademic Editor: Evgeny Imyanitov  \nReceived: 11 December 2023  \nRevised: 8 January 2024  \nAccepted: 11 January 2024  \nPublished: 15 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nMemorial Cancer Institute, Pembroke Pines, FL 33028, USA; [kshan@mhs.net](kshan@mhs.net) (K.S.S.); [sdalal@mhs.net](sdalal@mhs.net) (S.D.);  \n[dieuuyenvu@utexas.edu](dieuuyenvu@utexas.edu) (D.U.D.V.); [amilillonaraine@mhs.net](amilillonaraine@mhs.net) (A.M.M.-N.); [dguaqueta@mhs.net](dguaqueta@mhs.net) (D.G.);  \n[aergle@mhs.net](aergle@mhs.net) (A.E.)  \n* Correspondence: [erubin@mhs.net](erubin@mhs.net)  \nAbstract: Human epidermal growth factor receptor 2 (HER2) belongs to the ErbB family, a group of four transmembrane glycoproteins with tyrosine kinase activity, all structurally related to epidermal growth factor receptor (EGFR) . These tyrosine kinases are involved in the transmission of cellular signals controlling normal cell growth and differentiation. If this transmission goes awry, it can lead to dysregulated growth of the cell. HER2 specifically can be implicated in the pathogenesis of at least eight malignancies. HER2 positivity quickly became a well-characterized indicator of aggressiveness and poor prognosis, with high rates of disease progression and mortality. After realizing the implication of HER2, it first became investigated as a target for treatment in breast cancer, and later expanded to areas of research in other cancer types. To this day, the most therapeutic advancements of anti-HER2 therapy have been in breast cancer; however, there have been strong advancements made in the incorporation of anti-HER2 therapy in other cancer types as well. This comprehensive review dissects HER2 to its core, incorporating the most up to date information. The topics touched upon are discussed in detail and up to 200 published sources from the most highly recognized journals have been integrated. The importance of knowing about HER2 is exemplified by the groundbreaking advancements that have been made, and the change in treatment plans it has brought to the oncological world in the last twenty years. Since its groundbreaking discovery there have been significant breakthroughs in knowledge regarding the actual receptor, the receptors biology, its mechanism of action, and advancements in tests to detect HER2 and significant strides on how to best incorporate targeted treatment. Due to the success of this field thus far, the review concludes by discussing the future of novel anti-HER2 therapy currently in development that everyone should be aware of.  \nKeywords: HER2; HER2 discovery; HER2 role in cancers; HER 2 low; HER2DX; prognostic; predictive; biomarker; anti-HER therapies; HER2 landmark trials  \n1. Introduction  \nHuman epidermal growth factor receptor 2 (HER2) belongs to the ErbB family, a group of four transmembrane glycoproteins with tyrosine kinase activity, all structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. The ErbB family includes EGFR (also termed HER1 or ErbB1), HER2 (ErbB2), HER3 (ErbB3), an","cbCaigLlsrqa68xC","https://ap.wps.com/l/cbCaigLlsrqa68xC","pdf",1762787,46,"English","# Abstract\n# Keywords\n# 1. Introduction\n## HER2 in the ErbB family and signaling dysfunction\n## HER2 involvement across multiple cancers\n## HER2 genetic basis: amplification and dysregulation","[{\"question\":\"What biological role does HER2 play in cells?\",\"answer\":\"HER2 is a tyrosine kinase receptor involved in transmitting cellular signals that control normal cell growth and differentiation. If signaling goes awry, it can drive dysregulated cellular growth.\"},{\"question\":\"Why is HER2 considered clinically important in cancer?\",\"answer\":\"HER2 positivity is linked to aggressiveness and poor prognosis, with higher rates of progression and mortality. It is implicated in multiple malignancies with varying prevalence.\"},{\"question\":\"How has anti-HER2 targeted therapy evolved across cancer types?\",\"answer\":\"Anti-HER2 therapy was first developed and studied in breast cancer, where major therapeutic advances have occurred. The review highlights growing incorporation of anti-HER2 strategies into other cancer types and discusses future therapies under development.\"}]","Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers | PDF",1790039235,116,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6612f79b0d66d829399e5f939374915.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0efcdf490dfd646e184b574c97305d95.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69fc77e8ff2382f5bf3ee4b37398a5ce.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/729393f7af0e2e3381f569f3863a995e.webp",980,1385,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f3b031b78054ba7bc42d2a1b2ca9049.webp",979,1384]